Overview

Vitamin D in Fatty Liver Disease

Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the influence of vitamin D in reducing laboratory, elastographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive vitamin D (Plivit D3) while the other half will receive placebo
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Rijeka
Collaborators:
Pliva Hrvatska d.o.o.
University of Rijeka
Treatments:
Cholecalciferol
Dihydroxycholecalciferols
Ergocalciferols
Vitamin D
Vitamins